Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3389)	6/30/1999 10:34:00 AM
From: j_fir2	Respond to of 10280

Peter, thanks for going to the trouble to post those synopses. But the writers of those publications you cited, as well many doctors and much of the literature--throw descriptions of those modes of action around with regularity and (apparent) certainty. My tone reflects (perhaps it's obvious by now) rather more experience with these medicines than with, say, asthma or allergy medicines. Unless you think mentioning a "triple mode of action" in SEPR's (r)(r) fluoxetine was perhaps a marketing gesture, to entice investors and analysts into greater enthusiasm for the company's stock, such distinctions are a real part of the marketplace and of the practice of medicine, as far as I can tell. It is good to know that the scientists are determined to deduce the astounding complexities of the human body and particularly the brain (our brain) even if we laypeople get thoroughly and hopelessly confused before they are finished. Best wishes J'fir